



Artegraft® Collagen Vascular Graft
Instructions for use - English

Artegraft® Collagen Vascular Graft

Artegraft® Collagen Vascular Graft

(Model Numbers AG535, AG540, AG616, AG630, AG636, AG640, AG645, AG715, AG730, AG735, AG740, AG745, AG750, AG830, AG840, AG845, AG1015, AG1030)

Instructions for Use - English

STERILE LC



Rx only

Artegraft is of biological origin and the surgical staff must prepare the graft for implantation. The sterile graft is preserved in a tube filled with USP purified water and ethyl alcohol.

Not Made with Natural Rubber Latex

Non-Antigenic

Preparation for Implant



1. Fill basin with a minimum of 500 ml of 0.9% sodium chloride solution (sterile saline).
2. Remove graft from the container using sterile technique by grasping the support rod with fine-tipped forceps while container is held in semi-upright position.



3. Withdraw rod without touching top or outside rim & drain away excess alcohol from graft.
4. Immerse graft in basin during surgical preparation.
5. Flush alcohol from lumen before implanting. It is recommended to irrigate 7 to 8 times with ~30 ml of solution using bulb or piston syringe (with slip tip).



6. In a second basin, prepare a suggested ratio of 120 ml sterile saline solution with 2500 units of heparin for final rinse. See PRECAUTIONS. Using the same syringe or bulb, it is recommended to irrigate a minimum of one time with ~30 ml of solution using bulb or piston syringe (with slip tip).
7. Artegraft is manometry pressure tested and quality inspected. Before implanting, occlude one end of graft and pressure test with bulb or syringe filled with saline

Device Description

The Artegraft is composed of a section of specially selected bovine carotid artery that has been subjected to enzymatic digestion with ficin and tanned with dialdehyde starch.

Actions

The function and action of the Artegraft is simply to serve as a substitute conduit for blood where bypass or replacement of occluded or diseased arterial segments is required or to establish a conduit for hemodialysis.

Indications For Use

The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft. The use of the Artegraft for femoropopliteal bypass should be reserved for those patients where the autologous saphenous vein is absent or inadequate. It is also not recommended for reconstruction across the knee joint. However, in the absence of other viable alternatives, the surgeon may well find the benefit to risk ratio warrants its use as an attempted limb salvage procedure.

Contraindications

1. The Artegraft should not be used in venous or low pressure systems.
2. Once the package seal is broken, the graft should be used immediately. Any left-over material should be discarded.
3. The graft should not be used after the expiration date imprinted on the label.

Warnings

1. After the Artegraft has been removed from the container in the manner prescribed to preserve its sterility, it should be gently and thoroughly washed and rinsed to minimize carryover of preserving fluid. For aseptic removal and wash procedures, please see DOSAGE AND ADMINISTRATION Section.
2. Silk is not recommended for anastomosis. This suture occasionally was found to give rise to thick suture-line pannus in the dog.
3. The prosthesis is not to be used unless the capacity of the run-off vessel is adequate, as shown by pre-operative arteriography. Artegraft selection must be of comparable cross-sectional diameter to the host artery, particularly at the distal end, in order to avoid early thrombosis.
4. A minimum of ten days should be allowed after implantation before puncturing the graft with needles for hemodialysis. If edema appears around or distal to the graft, this should be allowed to resolve before cannulation.
5. Thrombosis of the graft has been reported from inadvertent external compression. Patients and those administering dialysis should be cautioned against compression of the graft for prolonged periods.

Precautions

1. In the event of early occlusion, re-exploration of the graft and removal of the thrombus with a LeMaitre catheter or other means often results in effective restoration of long-term patency. This procedure is somewhat easier to perform in the case of the Artegraft than with other prostheses.
2. Patients subjected to heparin anticoagulant rinse and flush should be confirmed to be heparin-induced thrombocytopenia (HIT) free, and of heparin associated allergic reactions. Some surgeons recommend systemic heparinization of the patient after completion of the preparatory dissection, with or without subsequent neutralization with protamine sulfate. Others rely on the periodic injection of diluted heparin into the arterial tree during the period of vascular clamping and anastomosis. Post-operative heparinization is usually not employed.
3. During implantation, meticulous technique is essential to avoid twisting and to achieve accurate approximation at the suture lines.
4. Clinical evidence suggests that subfascial, rather than subcutaneous, implantation in the lower extremity is the more satisfactory procedure.

For precautions regarding true aneurysms, please see ADVERSE REACTIONS Section.

Adverse Effects

Pseudointima formation and less frequently pseudodiaphragm formation may occur. Disruption of anastomoses, especially in the presence of infection, has

been observed and, in a few cases, transient low grade fever, the etiology, of which has not been obvious, has been experienced. In humans, immunologically-mediated rejection of the Artegraft has not been demonstrated..

True aneurysms have been reported. In view of this, patients with implanted Artegrafts should be observed so that appropriate action can be taken if an aneurysm should occur. This adverse reaction should also be considered when treating conditions in which extended periods of implantation are expected.

The complications encountered when the Artegraft is used as an AV shunt for dialysis include thrombosis, infection, aneurysm, and bleeding and/or hematoma. The true incidence of these will vary depending upon the frequency with which the graft is needle-punctured, the length of time the graft has been implanted and, very importantly, the condition of the patient, since the graft is recommended for use when more conventional measures prove inadequate. Less frequent, complications include "steal syndrome" and, in patients with heart disease, a significant incidence of high output congestive heart failure secondary to an arteriovenous shunt.

Dosage and Administration

To remove the Artegraft aseptically from its container, the container should be held in a semi-upright position. After carefully removing the cap without contaminating the rim of the container, the supporting rod and the graft itself should be lifted from the container with long fine-tipped thumb forceps. As soon as the graft itself becomes accessible, it should be grasped and removed from the container with the support rod and drain away excess alcohol from graft, care being taken not to touch the outside rim of the container.

The surgeon should immerse the graft in a large basin with a minimum of 500 ml of sterile 0.9% sodium chloride solution (sterile saline). It is recommended to irrigate the graft's lumen at least seven or eight times with ~30ml of solution using a bulb or piston syringe (with slip tip). A final irrigation and immersion should be performed. In a second basin, prepare a suggested ratio of 120ml sterile saline solution with 2500 units of heparin, unless HIT is diagnosed (see PRECAUTIONS). The graft is now considered ready for insertion into a patient.

The graft lot number and its length and diameter should be recorded on the patient's chart, as well as the actual length of the graft inserted into the patient. Since the Artegraft is intended as a conduit for arterial blood, no specific rules can be laid down as to the number and size of Artegrafts to be used in any given case, since individual requirements will vary widely.

However, accepted vascular surgical techniques should always be employed, including the use of non-crushing clamps to control the host artery and very gentle handling of the ends of the graft itself. Precise anastomosis without tension, bulging or twisting is mandatory.

The use of fine non-cutting rather than cutting-type needles helps avoid troublesome punctate bleeding at the anastomotic sites, particularly in the smaller diameter grafts.

If troublesome bleeding does occur, it may readily be controlled by simply applying a small bit of Artegraft as a patch to the bleeding area in a reverse manner so that the adventitia is in direct contact with adventitia.

In order to avoid possible snarling of the suture in the rather shaggy adventitia of the graft, it has been found convenient to start the stitch in the host artery rather than starting it in the graft. In so doing, care should be exercised to avoid the possibility of displacing an atheromatous plaque.

How Supplied

The Artegraft is packaged in a specially designed tube containing a sterilizing solution prepared with 1% propylene oxide in 40% aqueous U.S.P. ethyl alcohol. Each tube is enclosed in a set-up box for protection during shipment and storage.

The length and inner diameter of each Artegraft are specified on the packaging labels. The inner diameter of the Artegraft is approximate, rounded to the nearest mm, due to the nature of the biologic source material. The availability of graft diameters and lengths is dependent upon the animal source. Product codes and sizes are referenced in the chart below.

The approximate desired length and inner diameter of each graft should be specified when ordering; the nearest available sizes will be supplied upon confirmation.

NOTE: Outer diameters vary, but typically 1mm larger

Artegraft comes in the following sizes:

Model	Inner Diameter (mm)	Minimum Length (cm)
AG535	4 mm	35 cm
AG540	4 mm	40 cm
AG616	5 mm	15 cm
AG630	5 mm	30 cm
AG 636	5 mm	35 cm
AG640	5 mm	40 m
AG645	5 mm	45 cm
AG715	6 mm	15 mm
AG730	6 mm	30 cm
AG735	6 mm	35 cm
AG740	6 mm	40 cm
AG745	6 mm	45 mm
AG750	6 mm	50 cm
AG830	7 mm	30 cm
AG840	7 mm	40 cm
AG845	7 mm	45 cm
AG1015	8 mm	15 cm
AG1030	8 mm	30 cm








Limited Product Warranty; Limitation of Remedies

LeMaitre Vascular, Inc., warrants that reasonable care has been used in the manufacture of this device and that this device is suitable for the indication(s) expressly specified in these instructions for use. Except as explicitly provided herein, LEMAITRE VASCULAR (AS USED IN THIS SECTION, SUCH TERM INCLUDES LEMAITRE VASCULAR, INC., ITS AFFILIATES, AND THEIR RESPECTIVE EMPLOYEES, OFFICERS, DIRECTORS, MANAGERS, AND AGENTS) MAKES NO EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO THIS DEVICE, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) AND HEREBY DISCLAIMS THE SAME. This limited warranty does not apply to the extent of any abuse or misuse of, or failure to properly store, this device by the purchaser or any third party. The sole remedy for a breach of this limited warranty shall be replacement of, or refund of the purchase price for, this device (at LeMaitre Vascular's sole option) following the purchaser's return of the device to LeMaitre Vascular. This warranty shall terminate on the expiration date for this device.







IN NO EVENT SHALL LEMAITRE VASCULAR BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, SPECIAL, PUNITIVE, OR EXEMPLARY DAMAGES. IN NO EVENT WILL THE AGGREGATE LIABILITY OF LEMAITRE VASCULAR WITH RESPECT TO THIS DEVICE, HOWEVER ARISING, UNDER ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EXCEED ONE THOUSAND DOLLARS (US\$1,000), REGARDLESS OF WHETHER LEMAITRE VASCULAR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS, AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY REMEDY. THESE LIMITATIONS APPLY TO ANY THIRD-PARTY CLAIMS.


A revision or issue date for these instructions is included on the back page of these Instructions for Use for the user's information. If twenty-four (24) months has elapsed between this date and product use, the user should contact LeMaitre Vascular to see if additional product information is available.

Symbol Legend

English	Symbol Legend								Rx only
		Distributed By	Manufacturer	Catalog Number	Batch Code	Use-by Date	Quantity	Contents Sterile. Sterile LC: Device Sterilized Using Liquid Chemical Sterilant, compliant to EN/ISO 14160	Caution: U.S. Federal and other law restricts this device to sale by or on the order of a physician

Symbol Legend

	 ID					
English	Inner Diameter	Usable Length	Do not re-use.	Do Not Resterilize	Consult instructions for use	MR Safe



Distributed By:

LeMaitre Vascular, Inc.
Customer Service:
Tel: (781) 221-2266
Fax: (781) 221-2223




LeMaitre Vascular, Inc.
206 North Center Drive
North Brunswick, NJ 08902

Artegraft[®] Collagen Vascular Graft

Artegraft and LeMaitre are registered trademarks of LeMaitre Vascular, Inc.
©2022 LeMaitre Vascular, Inc. All rights reserved.

LS 012 Rev. V 11/22

Artegraft Collagen Vascular Graft



Patient ID _____


Surgeon _____

Date _____

Product Code _____

Lot Number _____

Artegraft Collagen Vascular Graft



Patient ID _____

Surgeon _____

Date _____

Product Code _____

Lot Number _____